show episodes
 
Artwork

1
BioBoss

John Simboli

Unsubscribe
Unsubscribe
Monthly
 
BioBoss is a podcast about leadership in the biopharma community. Hear directly from the founders and CEOs of today's most innovative companies. Listen in as Wyant Simboli Principal and branding veteran John Simboli poses the questions "What drives you? How do you create change? Why should people care?" to biopharma leaders and hear insights on this rapidly developing field.
  continue reading
 
Artwork

1
ASA Biopharm's Podcast

American Statistical Association (ASA) Biopharm. Section

Unsubscribe
Unsubscribe
Monthly
 
In this podcast series sponsored by Biopharmaceutical Section of American Statistical Association, key opinion leaders from pharmaceutical industry and regulatory agencies talk about upcoming statistical conferences and events, and discuss current issues in Biopharmaceutical statistics.
  continue reading
 
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is p ...
  continue reading
 
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved wi ...
  continue reading
 
Pharmacokinetic and Biopharmaceutics from the University of Oklahoma College of Pharmacy - PDF files of course material, Audio AND Video tutorials PHAR 7633 - Description and quantitation of factors affecting the absorption, distribution, and metabolism, and excretion of drugs. Development of appropriate dosage regimens and graphical analysis of drug concentration data sets. Bioequivalence and drug product testing. Drug analysis in biological matrix.
  continue reading
 
I’m an electrical engineer who enjoys listening to and sharing stories of ordinarily extraordinary women that work in STEM fields. The women featured on these episodes work in different STEM fields, are at different phases in their careers, and bring their unique perspectives and stories. I am endlessly fascinated by what these women do, how they have navigated their careers, balanced families, and why they made the career choices they did. Most STEM fields are dominated by men which makes f ...
  continue reading
 
Artwork

1
Inside Biotech

Ananta Wadhwa, Kathy Grotsch PhD, Gabriella Rubert, Leo Ying

Unsubscribe
Unsubscribe
Monthly
 
Inside Biotech is an exciting podcast from BCLA, which focuses on the science behind SoCal’s most innovative new biotech companies. This semi-monthly podcast, hosted by Gabriella Rubert, Ph.D. Candidate at UCLA and Podcast Lead at BCLA, is the perfect way for anyone interested in LA’s biotech community to stay informed about current progress and developments. Episodes feature conversations with scientists, entrepreneurs, investors, and more about the cutting-edge science that goes on inside ...
  continue reading
 
Loading …
show series
 
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, some cancer cells may remain in the body and cause recurrence or metastasis. This is where adjuvant therapi…
  continue reading
 
Dr. Audra Morse, Dean of the College of Engineering at Michigan Tech, is a distinguished professional with a Ph.D. in Civil Engineering and degrees in Environmental Engineering. Her journey from student to dean highlights the importance of rigorous academic challenges and hands-on learning in shaping successful careers in STEM. Dr. Morse emphasizes…
  continue reading
 
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…
  continue reading
 
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …
  continue reading
 
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potential new medicines for diseases of the eye? In this episode, Nick Kenny, Syneos Health CSO and interim podca…
  continue reading
 
YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors. Follow us on Linke…
  continue reading
 
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …
  continue reading
 
In this ToxChats© podcast, we spoke with Dr. René Meisner, Head of Safety Assessment at Denali Therapeutics, on using both transgenic and disease mouse models in a drug development program. Topics include considerations for program design, regulatory interactions, and the role of these mice moving forward. s for program design, regulatory interacti…
  continue reading
 
Dr. Syatta Wallace is an advocate for women in STEM and Founder of Janisaw Company. With over 15 years in developing gender-based programs, Dr. Wallace specializes in addressing the unique challenges women face in STEM careers. She shares her extensive experience in developing leadership and career development programs tailored for women in STEM. H…
  continue reading
 
In March 2024, the FDA approved a groundbreaking gene therapy for children with a specific form of leukodystrophy, offering hope to those with no current care options. However, the approval came with a hefty price tag, making headlines as the most expensive medicine in the world at $3,500,000 per patient. With the cost of innovation so high, what c…
  continue reading
 
We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …
  continue reading
 
This episode of Ordinarily Extraordinary Conversations with Women in STEM' features Charli Matthews, a champion for empowering women in STEM fields and trades. Charli Matthews is a visionary leader with a mission to Connect, Inform, and Educate the Global Pump Industry. Charli's groundbreaking online information and connection hub has reshaped indu…
  continue reading
 
After 7 years as the Syneos Health Podcast's founding and flagship host, Jeff Stewart is stepping down. Here, he reflects on his experience and bids farewell. It doesn't end here - stay tuned for new episodes with new host(s), coming soon! (Jeopardy! clip courtesy of Ken Jennings.) The views expressed in this podcast belong solely to the speakers a…
  continue reading
 
Patient assistance programs can make a huge difference for patients who need expensive medicines but can't afford them. In this episode, Jeff Stewart talks with Dave MacLeod, Managing Director, Value & Access at Syneos Health about the benefits and challenges of patient assistance programs, which provide free or low-cost medicines to eligible patie…
  continue reading
 
With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies wo…
  continue reading
 
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…
  continue reading
 
Ivan Godinez Director of Product Management at Proteintech (2:00) What does Ivan do for Proteintech? (4:10) Importance of single-cell level resolution and getting diverse data to answer scientific questions with different approaches (6:10) How did Ivan get to where he wanted? (8:12) Ivan's entrance into biotech, and subsequently, product management…
  continue reading
 
The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years. Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive backgr…
  continue reading
 
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…
  continue reading
 
Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at …
  continue reading
 
We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…
  continue reading
 
For the first time, the technology behind Wall Street and Formula One racing is being used in pharmaceuticals—and it’s offering unparalleled potential for innovation in clinical trial execution and healthcare delivery. In this episode, host Jeff Stewart is joined by Darren Coleman, the general manager of RxDataScience, a Syneos Health company, who …
  continue reading
 
We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…
  continue reading
 
Dr. Chanfeng Zhao is the VP of R&D Chemistry at TriLink BioTechnologies. She has over 25 years of experience in nucleotide and modified nucleotide chemistry for sequencing and genomics applications. She co-founded MyChem LLC, a company later acquired by TriLink, specializing in ultra-pure synthetic nucleotides. Chanfeng was the CSO and Co-founder o…
  continue reading
 
More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at http…
  continue reading
 
We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersecti…
  continue reading
 
To learn more about BCLA’s events and consulting visit https://www.bc-la.org/ Complete Genomics: https://www.completegenomics.com/company/about-us/ Joyee Yao’s LinkedIn: https://www.linkedin.com/in/joyee-yao-74901212/ Follow our Instagram @insidebiotech for updates about episodes and upcoming guests! To learn more about BCLA’s events and consulting…
  continue reading
 
We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business d…
  continue reading
 
Abigail Fritschel is about to graduate from Iowa State University with a degree in Aerospace Engineering. Abby was first on the podcast as Episode 13 when she had just graduated from high school in the summer of 2020. She's back to provide an update on college life, her college experience vs. her expectations, internships, Society of Women Engineer…
  continue reading
 
The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, a…
  continue reading
 
We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson is…
  continue reading
 
In this episode of the Driving Digital in Biopharma podcast, Samer Ansari, Head of Data, Digital, and Technology at Takeda Oncology, joins Tom Lehmann, Global Head of Accenture Life Sciences R&D, to discuss the role of digital in creating exceptional HCP and patient experiences. Through their shared passion for data and tech and the importance of u…
  continue reading
 
When it comes to launching a pharmaceutical product in today’s market—especially as an emerging company—strategic investment can make all the difference. Drawing from a recent study on investing for commercial success, Michael Sarshad, Managing Director in the Commercial Advisory Group at Syneos Health, discusses the key factors for successfully la…
  continue reading
 
We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challen…
  continue reading
 
Mentors meet with you, listen to you, and provide advice. Sponsors have influence, connections, and can speak to your talents, abilities, and potential in new opportunities. Learning how to distinguish between the two and identify a sponsor that can help support your key growth and access to future opportunities is a critical skill needed to suppor…
  continue reading
 
2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocate…
  continue reading
 
We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necess…
  continue reading
 
To learn more about SULA LABS visit https://www.sula-labs.com/ Follow our Instagram @insidebiotech for updates about episodes and upcoming guests! To learn more about BCLA’s events and consulting visit our website. Follow BCLA on LinkedInBy Katherine Merkling, Daniel Arce, Carys Layton, Gabriella Rubert, Serena Gao, Daniel Graves
  continue reading
 
We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger w…
  continue reading
 
Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (AMD). By the age of 75, roughly 1 in 3 people living in the United States will have some form of AMD, and a…
  continue reading
 
We love to hear from our listeners. Send us a message. The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed. Its CEO,…
  continue reading
 
Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech comp…
  continue reading
 
Loading …

Quick Reference Guide